PTC Therapeutics (PTCT) Receives News Impact Score of 0.10

News coverage about PTC Therapeutics (NASDAQ:PTCT) has trended somewhat positive this week, according to Alpha One Sentiment. The research firm, a service of Accern, rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. PTC Therapeutics earned a news impact score of 0.10 on Alpha One’s scale. Alpha One also assigned media stories about the biopharmaceutical company an impact score of 97 out of 100, indicating that recent media coverage is extremely likely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have effected AlphaOne Sentiment Analysis’s scoring:

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Shares of PTC Therapeutics (NASDAQ:PTCT) opened at 16.99 on Friday. The stock’s market capitalization is $583.03 million. PTC Therapeutics has a 52 week low of $4.03 and a 52 week high of $17.18. The stock’s 50 day moving average is $13.60 and its 200 day moving average is $12.28.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.88) by $0.03. PTC Therapeutics had a negative return on equity of 98.77% and a negative net margin of 143.80%. The firm had revenue of $26.50 million during the quarter, compared to the consensus estimate of $27.93 million. During the same quarter in the previous year, the company posted ($1.22) earnings per share. The business’s revenue was up 40.2% on a year-over-year basis. Analysts anticipate that PTC Therapeutics will post ($3.55) EPS for the current fiscal year.

Several brokerages have weighed in on PTCT. Citigroup Inc. set a $18.00 price target on PTC Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 7th. Zacks Investment Research downgraded PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Cowen and Company reiterated a “hold” rating on shares of PTC Therapeutics in a report on Thursday, March 16th. Royal Bank Of Canada cut their price target on PTC Therapeutics from $13.00 to $10.00 and set a “sector perform” rating for the company in a report on Thursday, March 16th. Finally, Barclays PLC downgraded PTC Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $20.00 to $13.00 in a report on Friday, March 3rd. Eight analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. PTC Therapeutics presently has an average rating of “Hold” and a consensus price target of $14.56.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/06/17/ptc-therapeutics-ptct-receives-news-sentiment-rating-of-0-10-updated.html.

In related news, Director Dawn Svoronos acquired 25,000 shares of the stock in a transaction on Tuesday, May 23rd. The stock was purchased at an average price of $13.49 per share, for a total transaction of $337,250.00. Following the completion of the transaction, the director now owns 25,000 shares of the company’s stock, valued at approximately $337,250. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 7.80% of the company’s stock.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply